Preclinical Study Using Parsortix Presented at Tumor Models Boston Summit
July 20 2017 - 08:00AM
Business Wire
Parsortix system demonstrates capabilities
for use in cancer drug research
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy
company, today announced the presentation of independent study data
by Western University on circulating tumor cell (CTC) analysis in
preclinical models of cancer metastasis at the Tumor Models Summit
in Boston on Thursday, July 20.
The study will be presented by Alison Allan, Ph.D., Associate
Professor, Departments of Anatomy & Cell Biology & Oncology
Schulich School of Medicine and Dentistry, Western University based
in Toronto, Canada.
The study findings demonstrate the potential use of
clinically-relevant CTC technologies such as ANGLE’s proprietary
Parsortix™ platform to enhance the translation of cancer biology
and highlight the importance of developing cancer drugs using
metastasis models, rather than just primary tumor pre-clinical
models.
Although a number of quantitative tools have been previously
developed to study in vivo metastasis, the detection and
quantification of rare metastatic events has remained challenging.
To reduce the incidence of metastatic disease, drug development
should target the metastatic process itself, which is the cause of
over 90 percent of cancer deaths. In particular, the use of
clinically-relevant CTC technologies such as the Parsortix system
will enhance the translation of cancer biology and new cancer
therapies from animal models to clinical trials.
In the study, Dr. Allan used three approaches – Flow Cytometry,
CellSearch®, and Parsortix – to capture and isolate CTCs of mouse
models with breast and prostate cancer. In vivo data showed that
Parsortix is best suited for this work for multiple reasons
including its ability to analyze CTC clusters (which have been
shown to be associated with aggressive disease) as well as the
option to isolate and recover cells for further analysis. The
Parsortix system’s epitope-independence (capturing all types of
CTCs) and its automated ease of use are also highlighted.
“Of the three types of liquid biopsy technology employed in
cancer management, the analysis of CTCs is the most advanced and
could potentially revolutionize the treatment of cancer patients,”
said Dr. Allan. “The presence of CTCs can be detected early in the
course of a cancer and is a fundamental prerequisite of metastasis.
Their identification offers great potential not only in the
diagnosis of patients but also in assessing their progression and
likely outcome. When comparing the three methods used, ANGLE’s
Parsortix system proved to be the most advanced in its ability to
harvest viable cells for downstream analysis, which is critical to
research and patient care.”
“The findings from Dr. Allan’s study show that ANGLE’s Parsortix
system continues to be evaluated positively when compared to other
CTC technologies, and has demonstrated pre-clinical utility as well
as the potential for clinical utility. A key advantage that
Parsortix now offers, which is not available with most other
approaches, is a low volume adaptor to enable the processing of
small volumes of mouse blood,” said Peggy Robinson, Vice President,
ANGLE North America, Inc.
The results of the study demonstrate the utility of CTCs in
pre-clinical tumor models. CTCs enable the monitoring of early
dissemination and kinetics of the metastatic process in real-time
and may lead to an increased understanding of metastatic biology.
Further, it could accelerate innovation in metastasis-specific drug
development and allow for timely assessment of a patient’s response
to a therapy.
Western University is a customer of ANGLE and its research work
is independent of the Company.
For more information about the conference, including the full
agenda, visit http://tumor-models.com/.
About ANGLE plc
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE’s cell separation technology is called the Parsortix™
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE’s Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug’s effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170720005622/en/
ANGLE plc, +44 1483 343434Andrew Newland, Chief
ExecutiveIan Griffiths, Finance DirectororCenkos Securities, +44
20 7397 8900Stephen Keys (Nominated adviser), Steve CoxRussell
Kerr (Sales)orWG Partners, +44 20 3705 9330David WilsonClaes
SpångorFTI ConsultingSimon Conway, Mo Noonan, Stephanie
Cuthbert, +44 20 3727 1000Kimberley Ha (US), +1 212 850
5612
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2023 to Mar 2024